A Decisive Milestone for Entering the European Market

Biocon Biologics, a subsidiary of India's leading biopharmaceutical company Biocon, has received final marketing authorization from the European Medicines Agency (EMA) for Evfraxy, a biosimilar to denosumab. This approval confirms the biosimilar's biological equivalence and safety compared to the originator drug, Prolia, from Amgen, and is effective until June 30, 2025, pending final authorization from the European Commission (EC). Evfraxy is a monoclonal antibody that inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand), a target protein that suppresses the formation and activation of osteoclasts, which break down bone, thereby reducing bone resorption. With this approval, Biocon is well-positioned to provide high-quality, affordable alternatives for the treatment of osteoporosis and bone loss in cancer patients across Europe.

Differentiation in a Fiercely Competitive Landscape

The European denosumab market is already highly competitive, with biosimilar products from global companies such as Sandoz's Jubbonti, Organon's Bildyos, and Alvotech's Kefdensis having received approvals. While Biocon Biologics is a late entrant in terms of market entry speed, it has secured the right to commercially launch Evfraxy in the European market from December 2, 2025, by resolving a patent dispute with Amgen, the originator company, early on. This agreement completely eliminates legal uncertainties and serves as a crucial stepping stone for establishing a stable distribution network. In the future, the company will strive to expand its market share through close collaboration with distribution partners, which is expected to positively influence the intensity of initial competition.

The Next Gateway to Successful Market Penetration

Following EMA approval, Biocon's key challenge is to negotiate pricing and reimbursement with national health authorities in each European country. As healthcare systems vary across countries, demonstrating reasonable cost-effectiveness is essential for securing actual prescriptions. Leveraging its superior price competitiveness compared to the originator product, Biocon aims to successfully gain prescription codes and enter hospital bidding markets, which will be a key factor in future revenue growth. Furthermore, it will simultaneously implement marketing strategies to continuously educate healthcare professionals and patients about the reliability of biosimilars and increase the rate of switching from the originator product.

A Catalyst for Global Revenue Growth

Prolia is a blockbuster drug that generated approximately $4.41 billion in global revenue in 2025. With the expiration of patents, the market is expected to be significantly impacted by biosimilar competition, and biosimilar products will replace Prolia. The global denosumab market is projected to grow rapidly to approximately $6.06 billion by 2030, driven by the aging population and the increasing availability of biosimilars. This European approval provides Biocon Biologics with a vast European territory, along with the US market (where the product is named Bosaya), which will serve as a key revenue driver for the company.